Performance promotion
Company announcement
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
- Letter to Non-Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
- Letter to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
- 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
- 2025 ANNUAL REPORT
- VOLUNTARY ANNOUNCEMENT RESULTS OF PRELIMINARY DATA FROM THE PHASE 1B FORTRESS CLINICAL STUDY OF NG-350A PRESENTED AT THE 2026 AACR
- VOLUNTARY ANNOUNCEMENT RESULTS OF PHASE III CLINICAL DATA OF DIROZALKIB FOR THE FIRST-LINE TREATMENT OF ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PRESENTED AT THE 2026 AACR
- INSIDE INFORMATION APPROVAL BY THE STOCK EXCHANGE REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION
- VOLUNTARY ANNOUNCEMENT APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR NEW INDICATION OF ANAPRAZOLE SODIUM
- INSIDE INFORMATION NOTIFICATION LETTER OF THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION
9th Floor, North Tower of CP Center, No.20 Jin He East Avenue,Chaoyang District,Beijing,China
Tel：010-5765 4567
Email：XZGROUP@xuanzhubio.com
Copyright © 轩竹生物科技有限公司保留所有权利 冀ICP备2020028968号-2 网站建设技术支持：唯引互动
